Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-… Read more
Harvard Apparatus Regenerative Technology Inc. (HRGN) - Net Assets
Latest net assets as of September 2025: $1.55 Million USD
Based on the latest financial reports, Harvard Apparatus Regenerative Technology Inc. (HRGN) has net assets worth $1.55 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.55 Million) and total liabilities ($992.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.55 Million |
| % of Total Assets | 61.04% |
| Annual Growth Rate | 24.22% |
| 5-Year Change | 186.4% |
| 10-Year Change | N/A |
| Growth Volatility | 186.78 |
Harvard Apparatus Regenerative Technology Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Harvard Apparatus Regenerative Technology Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Harvard Apparatus Regenerative Technology Inc. (2019–2024)
The table below shows the annual net assets of Harvard Apparatus Regenerative Technology Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.22 Million | +95.75% |
| 2023-12-31 | $1.65 Million | +66.43% |
| 2022-12-31 | $989.00K | +132.65% |
| 2021-12-31 | $-3.03 Million | -369.24% |
| 2020-12-31 | $1.12 Million | +3.31% |
| 2019-12-31 | $1.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Harvard Apparatus Regenerative Technology Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3559300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $102.91 Million | 3193.98% |
| Total Equity | $3.22 Million | 100.00% |
Harvard Apparatus Regenerative Technology Inc. Competitors by Market Cap
The table below lists competitors of Harvard Apparatus Regenerative Technology Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sutlej Textiles and Industries Limited
NSE:SUTLEJTEX
|
$14.81 Million |
|
ENVIVA INC. DL -001
F:XV6
|
$14.81 Million |
|
Tianci International, Inc. Common Stock
PINK:CIIT
|
$14.82 Million |
|
Visesh Infotecnics Limited
NSE:VISESHINFO
|
$14.82 Million |
|
Kocom Co. Ltd
KQ:015710
|
$14.80 Million |
|
INITECH Co. Ltd
KQ:053350
|
$14.80 Million |
|
Radiant Cash Management Services Limited
NSE:RADIANTCMS
|
$14.80 Million |
|
Fill Up Media SA
PA:ALFUM
|
$14.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harvard Apparatus Regenerative Technology Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,646,000 to 3,222,000, a change of 1,576,000 (95.7%).
- Net loss of 7,732,000 reduced equity.
- New share issuances of 6,482,000 increased equity.
- Other factors increased equity by 2,826,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.73 Million | -239.98% |
| Share Issuances | $6.48 Million | +201.18% |
| Other Changes | $2.83 Million | +87.71% |
| Total Change | $- | 95.75% |
Book Value vs Market Value Analysis
This analysis compares Harvard Apparatus Regenerative Technology Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.48x to 8.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.13 | $1.80 | x |
| 2020-12-31 | $0.12 | $1.80 | x |
| 2021-12-31 | $-0.28 | $1.80 | x |
| 2022-12-31 | $0.08 | $1.80 | x |
| 2023-12-31 | $0.12 | $1.80 | x |
| 2024-12-31 | $0.20 | $1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harvard Apparatus Regenerative Technology Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -239.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1798.14%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.38x
- Recent ROE (-239.98%) is above the historical average (-432.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -765.11% | 0.00% | 0.00x | 1.83x | $-8.44 Million |
| 2020 | -432.44% | 0.00% | 0.00x | 1.85x | $-4.98 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.68 Million |
| 2022 | -614.05% | 0.00% | 0.00x | 2.43x | $-6.17 Million |
| 2023 | -543.44% | -8684.47% | 0.04x | 1.59x | $-9.11 Million |
| 2024 | -239.98% | -1798.14% | 0.10x | 1.38x | $-8.05 Million |
Industry Comparison
This section compares Harvard Apparatus Regenerative Technology Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harvard Apparatus Regenerative Technology Inc. (HRGN) | $1.55 Million | -765.11% | 0.64x | $14.80 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |